What is the present valuation and projected CAGR of the nephrotic syndrome market?
The nephrotic syndrome market size has grown rapidly in recent years. It will grow from $0.87 billion in 2024 to $00.96 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to increasing the incidence of nephrotic syndrome, increasing genetic disorders, rising rates of obesity, increasing use of immunosuppressive medications, and growing impact of genetic factors.
The nephrotic syndrome market size is expected to see rapid growth in the next few years. It will grow to $1.44 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to rising Nephrotic Syndrome disease awareness, rise in prevalence of CKD, increasing prevalence of metabolic disorders, growing aging population, rising incidence of autoimmune diseases. Major trends in the forecast period include telemedicine and remote monitoring, innovative drug delivery systems, innovation in treatment modalities, advancements in biotechnology, and integration of digital health technologies.
Get Your Free Sample of The Global Nephrotic Syndrome Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21228&type=smp
What key drivers have fueled the nephrotic syndrome market’s development over the years?
The increasing incidence of kidney diseases is expected to propel the growth of the nephrotic syndrome market going forward. Kidney diseases refer to any conditions or disorders impairing the kidneys’ function, which are vital organs responsible for filtering waste and excess fluids from the blood. The increasing incidence of kidney diseases is attributed to factors such as diabetes, hypertension, obesity, aging populations, and lifestyle changes, including high sodium intake and inadequate hydration. Nephrotic syndrome contributes to kidney diseases by causing damage to the glomeruli, impairing the kidney’s ability to filter waste and retain essential proteins. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the percentage of chronic kidney disease (CKD) mortality in Australia increased from 4.2% in 2021 to 6.2% in 2022. Therefore, the increasing incidence of kidney diseases is driving the growth of the nephrotic syndrome market.
What is the segmentation for the nephrotic syndrome market?
The nephrotic syndrome market covered in this report is segmented –
1) By Type: Drugs, Devices
2) By Diagnosis Tests: Urinalysis, Glomerular Filtration Rate (GFR), Blood Test, Kidney Biopsy, Computerized Tomography (CT) Scan
3) By Application: Clinics, Hospitals, Speciality Centres, Other Applications
Subsegments:
1) By Drugs: Steroids, Immunosuppressants, Diuretics, ACE Inhibitors Or ARBs, Other Drugs
2) By Devices: Dialysis Machines, Peritoneal Dialysis Catheters, Hemodialysis Catheters, Kidney Replacement Therapy Devices
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/nephrotic-syndrome-global-market-report
Who are the most influential companies in the nephrotic syndrome market?
Major companies operating in the nephrotic syndrome market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Eli Lilly and Company, Asahi Kasei Corporation, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Vertex Pharmaceuticals, Chugai Pharmaceutical Co. Ltd., Mallinckrodt Company, Evotec SE, Travere Therapeutics Inc., Aurinia Pharmaceuticals Inc., Orbis Biosciences Inc., Alpine Immune Sciences, Kezar Life Sciences, Zenyaku Kogyo Co. Ltd
What are the top industry trends projected to impact the nephrotic syndrome market?
Major companies operating in the nephrotic syndrome market are focusing on developing innovative formulations, such as loop diuretic injections, to improve fluid management and reduce edema in nephrotic syndrome patients. Loop diuretic Injection refers to an injectable medication that inhibits sodium and chloride reabsorption in the loop of Henle, promoting rapid urine production. It is used to treat conditions such as acute pulmonary edema, heart failure, and severe hypertension by reducing fluid overload. For instance, in March 2024, Avenacy Inc., a US-based pharmaceutical company, launched furosemide for Injection in the U.S., a generic equivalent to Lasix, approved by the Food and Drug Administration for treating edema related to heart failure, liver cirrhosis, and kidney diseases. Packaged in 25-unit packs of 100 mg/10 mL doses, this launch is part of Avenacy’s broader strategy to expand its injectable medication portfolio, with plans to launch over 20 products in 2024. This drug is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome.
What are the major regional insights for the nephrotic syndrome market, and which region holds the top position?
North America was the largest region in the nephrotic syndrome market in 2024. The regions covered in the nephrotic syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Nephrotic Syndrome Market Report 2025 Offer?
The nephrotic syndrome market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Nephrotic syndrome is a kidney disorder characterized by excessive protein loss in the urine (proteinuria), low levels of protein in the blood (hypoalbuminemia), high cholesterol levels (hyperlipidemia), and swelling (edema), especially in the legs, feet, and around the eyes. It occurs due to damage to the glomeruli, the kidney’s filtering units, which allows the protein to leak into the urine.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21228
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
